MedPath

Treatment of Bleeding Gums with Unani Medicine Sunoon-e-Mukhrij-e-Rutubat.

Phase 2
Conditions
Health Condition 1: K051- Chronic gingivitisHealth Condition 2: L00-L99- Diseases of the skin and subcutaneous tissue
Registration Number
CTRI/2018/08/015447
Lead Sponsor
Central Council For Research In Unani Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients of either sex in the age group 18-65 years.

2. Patients having Lissa-e-Damiya (Bleeding gums) with or without any of the following symptoms:

Painful chewing

Waram al-Lissa (Gingival swelling)

Humra al-Lissa (Gingival erythema)

Dhahab Maâ?? al-Asnan (Sensitive teeth)

Exclusion Criteria

1. Bleeding gums accompanied by impaired neurological functions (loss of balance, weakness, numbness, or speech disturbances), double vision, seizures, mental disturbances, and loss of consciousness.

2. Bleeding gums accompanied by persistent nausea, vomiting, fever and stiff neck.

3. Presence of a periodontal abscess as diagnosed from clinical examination of the bleeding gums.

4. Presence of concomitant bleeding due to any other condition such as soft-tissue lesions (e.g., aphthous/ traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis) or multiple hard-tissue (e.g., carious).

5. Known case of Hemophilia, Low platelet count (thrombocytopenia) and von Willebrand disease (VWD) etc.

6. History or clinical evidence of chronic diseases requiring long-term treatment, e.g., DM, hypertension, tuberculosis, HIV etc

7. Pregnant and lactating women.

8. History of Hypersensitivity to the study drug or any of its ingredients.

9. History of addiction (alcohol, drugs,tobacco)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in sign and symptoms ofLissa-e-Damiya (Bleeding Gums)Timepoint: 7 days
Secondary Outcome Measures
NameTimeMethod
Hematological and biochemical assessments for safetyTimepoint: seven days
© Copyright 2025. All Rights Reserved by MedPath